Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
S Ombelet, D Castanares‐Zapatero… - Journal of medical …, 2024 - Wiley Online Library
Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
[HTML][HTML] Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
AS Cha-Silva, MB Gavaghan, T Bergroth… - American Journal of …, 2024 - journals.lww.com
Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the …
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
Molnupiravir's real-world effectiveness in COVID-19 non-hospitalized patients at high risk of severe disease: a single-center study
I Gmizic, N Todorovic, M Sabanovic, N Kekic… - medRxiv, 2023 - medrxiv.org
Objective To assess the real-world effectiveness of molnupiravir (MOL) in reducing the need
for hospitalization in at-risk, non-hospitalized patients with confirmed COVID-19. Methods A …
for hospitalization in at-risk, non-hospitalized patients with confirmed COVID-19. Methods A …